Autopsy report · NCT00331045

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

“Subject registration did not proceed as expected; difficult to complete within scheduled time frame; prematurely terminated w/ 21 subjects randomized.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 8 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sponsor type

Industry

Conditions

Cancer; Constipation

Interventions

alvimopan; Placebo; Alvimopan 0.5 mg/day; Alvimopan 1 mg/day

Participants

21

Trials that died the same way

• GLP-1 and Non-exercise Activity Thermogenesis in RHZ
  “Terminated because of insufficient number of subjects included.” (62% match in meaning)
• Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
  “Ended early due to inability to identify eligible subjects” (62% match in meaning)
• BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling
  “recruitment of subjects was halted prematurely. recruiting subjects halted prematurely” (61% match in meaning)
• Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas
  “Was not able to recruit patients for randomization.” (60% match in meaning)
• Evaluation of Potential Allergenicity of New Soybean Varieties
  “insufficient subjects recruited in allotted time” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.